Paragon 28 announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The system uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surface.
The addition of TenoTac 2.0 bolsters Paragon 28’s hammertoe product offering, which includes the Paratrooper™ Plantar Plate System, HammerTube™ Hammertoe System, Mini-Monster® Screw System, and JAWS Staple System.
Paragon 28’s CEO, Albert DaCosta, said, “With the launch of TenoTac™ 2.0, we further refined our initial offering to allow surgeons greater control and precision to address the unique needs of each patient. TenoTac™ 2.0 adds to our growing portfolio of soft tissue products and the Hammertoe segment, with opportunities for significant improvements in patient outcomes.”
Paragon 28 announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The system uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surface.
The addition of TenoTac 2.0...
Paragon 28 announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The system uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surface.
The addition of TenoTac 2.0 bolsters Paragon 28’s hammertoe product offering, which includes the Paratrooper™ Plantar Plate System, HammerTube™ Hammertoe System, Mini-Monster® Screw System, and JAWS Staple System.
Paragon 28’s CEO, Albert DaCosta, said, “With the launch of TenoTac™ 2.0, we further refined our initial offering to allow surgeons greater control and precision to address the unique needs of each patient. TenoTac™ 2.0 adds to our growing portfolio of soft tissue products and the Hammertoe segment, with opportunities for significant improvements in patient outcomes.”
Copy to clipboard 
